You're invited to attend our webinar on
Enhancing Your Esophageal Program by Improving Risk Stratification of Patients with Barrett’s Esophagus
Hear from GI pathologist, Robert D. Odze, MD, FRCPc, along with gastroenterologist, Anthony Infantolino, MD, AGAF, FACG, FACP of Jefferson Health. Practical application of TissueCypher in patient workflow and compelling case studies will be reviewed.
Three million people in the U.S. have Barrett's Esophagus, a known precursor to esophageal cancer. Until now, identifying which patients are at greatest risk for esophageal cancer has been impossible. Cernostics is looking to change that… Learn how
TissueCypher® Further Validated to Accurately Risk Stratify Barrett’s Esophagus Patients with Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences... Read More
Cernostics Announces Formation of Distinguished Medical Advisory Board Including Top Specialists in All Facets of Esophageal Disease... Read More
Blinded Independent Validation Study of Tissue Systems Pathology Test in Determining Risk of Progression to Esophageal Cancer in Patients with Barrett’s Esophagus to be Presented at DDW 2019... Read More